Answers are grounded in this paper and cite their sources.
Various monoclonal antibodies (mAb) target immune system molecules to enhance immunity by costimulating T cells (i.e., CD137, OX40, CD40, GITR) or interfering in coinhibitory signals (i.e., CTLA-4, PD-1). These powerful agents can be guided by cancer vaccines to enhance immunity against tumor but not self tissues. Clinically powerful therapeutic synergies are at hand.
No takes yet. Share an insight, caveat, or question.
Melero et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: